Priya Rastogi

Priya Rastogi

UNVERIFIED PROFILE

Are you Priya Rastogi?   Register this Author

Register author
Priya Rastogi

Priya Rastogi

Publications by authors named "Priya Rastogi"

Are you Priya Rastogi?   Register this Author

52Publications

1649Reads

45Profile Views

Assessment of effect size and power for survival analysis through a binary surrogate endpoint in clinical trials.

Stat Med 2019 Feb 27;38(3):301-314. Epub 2018 Sep 27.

Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/sim.7981DOI Listing
February 2019

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

N Engl J Med 2019 02 5;380(7):617-628. Epub 2018 Dec 5.

From the German Breast Group, Neu-Isenburg (G.M., S.L., H.H.F., P.W.), the Center for Hematology and Oncology Bethanien, Frankfurt (S.L.), the AGO-B and HELIOS Klinikum Berlin-Buch, Berlin (M.U.), the National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg (A.S.), Evangelische Kliniken Gelsenkirchen, Gelsenkirchen (H.H.F.), the Arbeitsgemeinschaft Gynäkologische Onkologie - Breast and Sana Klinikum Offenbach, Offenbach (C.J.), the Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), and Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg (P.W.) - all in Germany; the National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-S.H.); Instituto do Câncer do Estado de São Paulo, São Paulo (M.S.M.); the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation and Orlando Health University of Florida Health Cancer Center, Orlando (E.P.M.); the NSABP Foundation and Allegheny Health Network Cancer Institute (N.W.) and the NSABP Foundation and University of Pittsburgh Cancer Institute, School of Medicine (P.R.), Pittsburgh; Hospital Universitario La Paz-Instituto de Investigación Hospital Universitario La Paz, Madrid (A.R.); Institut Régional du Cancer de Montpellier, Université de Montpellier, INSERM Unité 1194, Montpellier, France (W.J.); the NSABP Foundation and Providence Portland Medical Center, Portland, OR (A.K.C.); the National Cancer Institute, Mexico City (C.A.-S.); the NSABP Foundation and Stanford University School of Medicine, Stanford (I.L.W.), and Genentech, South San Francisco (L.H.L., D.T., M.S., S.M.S.) - both in California; Yale University School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, CT (M.P.D.); the Ireland Cooperative Oncology Research Group, Dublin (J.P.C.); Fudan University Shanghai Cancer Center (Z.S.) and Roche (China) Holding (H.W.), Shanghai; the Cancer Center Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy (E.R.C.); F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom (H.D.); and the NSABP Foundation and Virginia Commonwealth University Massey Cancer Center, Richmond (C.E.G.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1814017
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1814017DOI Listing
February 2019

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

J Clin Oncol 2018 Sep 13:JCO1800242. Epub 2018 Sep 13.

Andrew D. Seidman, Memorial Sloan Kettering Cancer Center; Dawn L. Hershman, Columbia University, New York, NY; Louise Bordeleau, Hamilton Health Sciences and Canadian Cancer Trials Group, Hamilton, Ontario, Canada; Louis Fehrenbacher, Kaiser Permanente, Vallejo, CA; William E. Barlow, Cancer Research and Biostatistics, Seattle, WA; Jane Perlmutter, Gemini Group, Ann Arbor, MI; Lawrence Rubinstein, Jennifer Fallas Hayes, and Larissa A. Korde, National Cancer Institute; Lynn Pearson Butler, The Emmes Corporation, Rockville; Suparna B. Wedam, Julia A. Beaver, and Laleh Amiri-Kordestani, US Food and Drug Administration, Silver Spring; Jo Anne Zujewski, JZ Oncology, Bethesda, MD; Mary Lou Smith, Research Advocacy Network, Plano, TX; Meredith M. Regan, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and Priya Rastogi, University of Pittsburgh Medical Center, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00242
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00242DOI Listing
September 2018

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.

J Clin Oncol 2018 04 14;36(11):1073-1079. Epub 2018 Feb 14.

Irene L. Wapnir, Stanford University School of Medicine, Stanford, CA; Karen N. Price and Shari Gelber, Frontier Science and Technology Research Foundation, Richard D. Gelber, Frontier Science and Technology Research Foundation, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Harvard Medical School, Meredith M. Regan, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Stewart J. Anderson, University of Pittsburgh Graduate School of Public Health; Priya Rastogi, University of Pittsburgh Cancer Institute; Norman Wolmark, Allegheny Health Network Cancer Institute, Pittsburgh, PA; André Robidoux, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec; Alexander H.G. Paterson, Tom Baker Cancer Centre, Calgary, Alberta, Canada; Miguel Martín, CIBERONC, Instituto de Investigación Sanitaria Gregorio Marañon, Universidad Complutense, Madrid; José Manuel Baena-Cañada, Hospital Puerta del Mar, Cádiz, Spain; Johan W.R. Nortier, Leids Universitair Medisch Centrum, Leiden, Netherlands; Mothaffar F. Rimawi, Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St. Gallen; Stefan Aebi, Lucerne Cantonal Hospital and University of Bern, Switzerland; Eleftherios P. Mamounas, Orlando Health University of Florida Health Cancer Center, Orlando, FL; Charles E. Geyer Jr, Virginia Commonwealth University Massey Cancer Center, Richmond, VA; and Alan S. Coates, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5719DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891132PMC
April 2018

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.

J Clin Oncol 2017 Dec 26;35(35):3942-3948. Epub 2017 Oct 26.

All authors: National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Reena S. Cecchini, Priya Rastogi, Jong-Hyeon Jeong, and Adam M. Brufsky, University of Pittsburgh; Priya Rastogi and Adam M. Brufsky, Magee-Womens Hospital; Norman Wolmark, Allegheny Health Network Cancer Institute, Pittsburgh, PA; Patricia A. Ganz, University of California at Los Angeles, Los Angeles; Louis Fehrenbacher, Kaiser Permanente, Vallejo; Jonathan Polikoff, Kaiser Permanente, San Marco, CA; Edward H. Romond, University of Kentucky, Lexington, KY; Charles E. Geyer Jr, Virginia Commonwealth University, Richmond, VA; Sandra M. Swain and John L. Zapas, MedStar Washington Hospital Center, Washington, DC; Howard M. Gross, Dayton National Cancer Institute Community Oncology Research Program (NCORP), Dayton, OH; Patrick J. Flynn, Metro-Minnesota Community Clinical Oncology Program (CCOP), Woodbury, MN; Tanya A. Wahl, Fred Hutchinson Cancer Research Center, Seattle, WA; Thomas E. Seay, Atlanta Regional CCOP, Atlanta, GA; James L. Wade III, Heartland NCORP, Decatur, IL; David D. Biggs, Christiana Care Health System, Newark, DE; James N. Atkins, Southeast Clinical Oncology Research Consortium NCORP, Goldsboro, NC; and Eleftherios P. Mamounas, Orlando Health, Orlando, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.1165DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721228PMC
December 2017

Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP).

Chin Clin Oncol 2017 Feb;6(1)

National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2017.02.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731663PMC
February 2017

Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.

Bone 2016 09 24;90:123-6. Epub 2016 Mar 24.

Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2016.03.010DOI Listing
September 2016

Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study.

Springerplus 2016 9;5:422. Epub 2016 Apr 9.

School of Nursing, University of Pittsburgh, 3500 Victoria Street, Pittsburgh, PA 15261 USA ; Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, 130 De Soto Street, Pittsburgh, PA 15261 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40064-016-2061-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826652PMC
April 2016

Metastatic HER2-Positive Breast Cancer: Tailoring Treatment Un-'TIL' We Get It Right...

Oncology (Williston Park) 2016 Feb;30(2):156, 158-9

View Article

Download full-text PDF

Source
February 2016

Drug development: neoadjuvant opportunities in breast cancer.

Am Soc Clin Oncol Educ Book 2013 :73-9

From the University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Texas Southwestern Medical Center, Dallas, TX; MD Anderson Cancer Center Orlando, Orlando, FL; University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.73DOI Listing
November 2015

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

J Clin Oncol 2015 Aug 22;33(24):2600-8. Epub 2015 Jun 22.

Ciara C. O'Sullivan and Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Ian Bradbury, Christine Campbell, and Eileen Holmes, Frontier Science, Inverness-shire, Scotland; Marc Spielmann and Suzette Delaloge, Institut de Cancérologie Gustave Roussy, Villejuif, France; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Heikki Joensuu, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Joseph P. Costantino and Priya Rastogi, University of Pittsburgh, Pittsburgh, PA; Dimitrios Zardavas, Breast International Group; Karla V. Ballman, Mayo Clinic, Rochester, MN; Evandro de Azambuja and Martine Piccart-Gebhart, Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium; and Richard D. Gelber, Harvard Medical School, Harvard T.H. Chan School of Public Health, Dana-Farber Cancer Institute, and Frontier Science and Technology Research Foundation, Boston, MA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534523PMC
http://dx.doi.org/10.1200/JCO.2015.60.8620DOI Listing
August 2015

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

J Clin Oncol 2015 Apr 5;33(12):1340-7. Epub 2015 Jan 5.

Katherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/12/1340.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.56.2439
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.2439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397278PMC
April 2015

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

J Natl Cancer Inst 2015 Mar 4;107(3). Epub 2015 Mar 4.

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada (PJG); NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Kingston, Ontario, Canada (WRP, LES, BEC); NCIC Clinical Trials Group, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada (KAG); Dana Farber Cancer Institute, Harvard Medical School, Boston, MA (JAL); Columbia University Medical Center, New York, NY (DLH); National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA (PR); Vanderbilt-Ingram Medical Center, Vanderbilt University Medical Center, Nashville, TN (IAM); Mayo Clinic College of Medicine, Rochester, MN (TJH); Centre de recherche du CHU de Québec, Unité de recherche en santé des populations Hôpital du Saint-Sacrement, Quebec, Quebec, Canada (JL); National Cancer Research Institute Breast Clinical Studies Group, London, UK (AMT); Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada (KIP); Juravinski Cancer Center at Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada (TJW, SDM); Allan Blair Cancer Centre, Regina, Saskatchewan, Canada (HIC); British Columbia Cancer Agency, Fraser Valley Center, Surrey, British Columbia, Canada (CDO); University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada (KST); British Columbia Cancer Agency - Vancouver Island Center, University of British Columbia, British Columbia, Canada (VB); Ontario Cancer Institute, University Health Network, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (VS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565534PMC
March 2015

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

J Clin Oncol 2014 Nov 20;32(33):3744-52. Epub 2014 Oct 20.

Edith A. Perez, Gerardo Colon-Otero, the Mayo Clinic, Jacksonville; Eleftherios Mamounas, University of Florida Health Cancer Center-Orlando Health, Orlando, FL; Edward H. Romond, University of Kentucky, Lexington, KY; Vera J. Suman, Mayo Clinic, Rochester, MN; Jong-Hyeon Jeong, Priya Rastogi, University of Pittsburgh; Nancy E. Davidson, University of Pittsburgh Cancer Institute; Norman Wolmark, Allegheny General Hospital, Pittsburgh, PA; George Sledge, Stanford University School of Medicine, Stanford; Silvana Martino, The Angeles Clinic and Research Institute, Santa Monica, CA; Charles E. Geyer Jr, Virginia Commonwealth University Massey Cancer Center, Richmond, VA; Julie Gralow, University of Washington/Seattle Cancer Care Alliance, Seattle, WA; Sandra M. Swain, MedStar Washington Hospital Center, Washington, DC; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jo Anne Zujewski, National Institutes of Health, Rockville, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.5730DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805PMC
November 2014

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

J Natl Cancer Inst 2013 Dec 21;105(23):1782-8. Epub 2013 Nov 21.

Affiliations of authors: National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA (J-HJ, HB, PR, LF, EHR, SMS, EPM, DLW, CEG,Jr, JPC, NW, SP); Division of Pathology, NSABP (KLP-G, CK, NT, PGG, DF, YT, OLB, AL, S-IK, MLR, MYR, NLB, S-RK, ZDH); Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (J-HJ, HB, JPC); PhenoPath Laboratories, PLLC, Seattle, WA (LCG); Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX (NS); Department of Pathology, University Medical Center Hamburg-Eppendorf, University Cancer Center, Hamburg, Germany (EB); Department of Pathology, Catholic University of Korea, Seoul, Republic of South Korea (AL); University of Pittsburgh Cancer Institute, Pittsburgh, PA (PR); Department of Oncology, Kaiser Permanente, Northern California, Vallejo, CA (LF); Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY (EHR); Department of Medicine, Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC (SMS); Department of Surgery, MD Anderson Cancer Center Orlando, Orlando, FL (EPM); Department of Medicine, Virginia Commonwealth University, Richmond, VA (CEG, Jr); Department of Surgery, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA (DLW, NW); Department of Biomedical Science, Severance Biomedical Science Institute, and Department of Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea (SP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848987PMC
December 2013

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

J Clin Oncol 2013 Sep 12;31(26):3197-204. Epub 2013 Aug 12.

Sandra M. Swain, Gong Tang, Charles E. Geyer Jr, Priya Rastogi, James N. Atkins, Paul P. Donnellan, Louis Fehrenbacher, Catherine A. Azar, André Robidoux, Jonathan A. Polikoff, Adam M. Brufsky, David D. Biggs, Edward A. Levine, John L. Zapas, Louise Provencher, Soonmyung Paik, Joseph P. Costantino, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project (NSABP); Norman Wolmark, Allegheny General Hospital, Allegheny Health Network; Gong Tang and Joseph P. Costantino, NSABP Biostatistical Center and University of Pittsburgh Graduate School of Public Health; Priya Rastogi, University of Pittsburgh Cancer Institute; Adam M. Brufsky, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA; Sandra M. Swain, MedStar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University, Richmond, VA; James N. Atkins, Southeast Cancer Control Consortium-Community Clinical Oncology Program, Goldsboro; Edward A. Levine, Wake Forest University, Winston-Salem, NC; Paul P. Donnellan, University Hospital, Galway, and the All-Ireland Cooperative Oncology Research Group, Dublin, Ireland; Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo; Jonathan A. Polikoff, Kaiser Permanente Southern California, San Diego, CA; Catherine A. Azar, Kaiser Permanente, Denver, CO; André Robidoux, Centre hopitalier de l'Université de Montréal (CHUM), Montréal; Louise Provencher, CHU de Québec, Hôpital du Saint-Sacrement, Québec City, QC, Canada; David D. Biggs, Helen F. Graham Cancer Center, Christiana Care Health System, Newark, DE; John L. Zapas, Medstar Franklin Square Medical Center, Baltimore, MD; Donald W. Northfelt, Mayo Clinic Arizona, Scottsdale, AZ; and Eleftherios P. Mamounas, MD Anderson Cancer Center, Orlando, FL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2013/08/12/JCO.2012.48
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.48.1275
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.48.1275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757290PMC
September 2013

Reply to V. Pitini et al.

J Clin Oncol 2013 Jun;31(17):2225

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.3701DOI Listing
June 2013

Trastuzumab as single agent therapy for HER2-positive metastatic breast cancer.

Onkologie 2010 21;33(8-9):420-1. Epub 2010 Jul 21.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000318991DOI Listing
January 2011

The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity.

Oncol Nurs Forum 2011 Jan;38(1):85-9

University of Pittsburgh School of Nursing, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1188/11.ONF.85-89DOI Listing
January 2011

Targeting alternative pathways in HER2-positive breast cancer.

Authors:
Priya Rastogi

Oncology (Williston Park) 2010 Apr;24(5):415-6

University of Pittsburgh, Cancer Institute, Division of Hematology-Oncology, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
April 2010

Chemoprevention in postmenopausal women.

Authors:
Priya Rastogi

Menopause 2008 Jul-Aug;15(4 Suppl):810-5

Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00042192-200815041-000
Publisher Site
http://dx.doi.org/10.1097/gme.0b013e318178863eDOI Listing
December 2008

What do perceived cognitive problems reflect?

J Support Oncol 2008 May-Jun;6(5):238-42

University of Pittsburgh School of Nursing, 3500 Victoria Street, Suite 415, Pittsburgh, PA 15261, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833096PMC
September 2008

Update on breast cancer prevention.

Oncology (Williston Park) 2003 Jun;17(6):799-805; discussion 808-10, 813

Breast Cancer Prevention Program, Magee-Women's Hospital/University of Pittsburgh, Department of Medicine, Section of Hematology/Oncology, School of Medicine, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
June 2003